Trading Information Summary - On February 5, 2026, Zhendemedical (603301) closed at 69.95 yuan, down 0.63%, with a turnover rate of 0.35% and a trading volume of 9,325 lots, amounting to 65.14 million yuan [1] - On the same day, the net inflow of main funds was 339.93 thousand yuan, accounting for 5.22% of the total trading volume; the net inflow of speculative funds was 558.76 thousand yuan, accounting for 8.58% of the total trading volume; while retail investors experienced a net outflow of 898.69 thousand yuan, accounting for 13.8% of the total trading volume [1][2] Company Announcement Summary - Zhendemedical announced a change in the project quality reviewer for the 2025 audit, with Wang Wen taking over from Zheng Chuanxian due to work adjustments [1] - Wang Wen has been a certified public accountant since 2011 and has been providing audit services for the company since 2025, having signed or reviewed audit reports for multiple listed companies in the past three years [1] - The change in the quality reviewer will not affect the normal progress of the company's 2025 financial statement and internal control audit [1][2]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 振德医疗用品股份有限公司（以下简称"公司"）于2025年4月24日和2025年5月19日分别召开了第三届董 事会第二十次会议和2024年年度股东大会，审议通过了《关于续聘会计师事务所的议案》，同意聘任天 健会计师事务所（特殊普通合伙）（以下简称"天健"）为公司2025年度财务审计及内部控制审计机构， 具体内容详见公司于2025年4月26日和2025年5月20日在上海证券交易所网站披露的相关公告。 公司于2026年2月4日收到天健出具的《关于变更项目质量复核人的函》，现将具体情况公告如下： 一、项目质量复核人变更情况 天健作为公司2025年度财务审计及内部控制审计机构，原委派郑传贤先生作为项目质量复核人为公司提 供审计服务。现因郑传贤先生工作调整，天健委派王文先生接任郑传贤先生为项目质量复核人继续为公 司提供2025年度审计工作。 二、变更后项目复核人情况 1、基本信息 王文先生，2011年起成为中国注册会计师，2011年开始从事上市公司审计，2011年开始在天健执业， 2025年 ...

Core Viewpoint - The company announced a change in the project quality reviewer for its 2025 financial audit, appointing Wang Wen as the new reviewer following the adjustment of the previous reviewer, Zheng Chuanxian [2][4]. Group 1: Change of Project Quality Reviewer - The company received a letter from Tianjian regarding the change of the project quality reviewer, with Wang Wen replacing Zheng Chuanxian due to the latter's work adjustment [2]. - Wang Wen has been a certified public accountant since 2011 and has been involved in auditing listed companies, including providing audit services for the company since 2025 [3]. Group 2: Independence and Integrity Record - Wang Wen has no violations of the independence requirements as per the Chinese Certified Public Accountant Independence Standards and has not faced any criminal or administrative penalties in the last three years [4]. - The transition of responsibilities during this change has been orderly, ensuring that the change will not adversely affect the company's 2025 financial statement audit and internal control audit [4].

Group 1 - The stock price of Zhendemedical (603301) closed at 70.39 yuan on February 4, 2026, with an increase of 2.07% and a turnover rate of 0.58% [1] - The trading volume was 15,500 shares, with a total transaction amount of 108 million yuan [1] - On February 4, the net inflow of main funds was 3.7659 million yuan, accounting for 3.5% of the total transaction amount [2] Group 2 - Zhendemedical announced a change in the project quality reviewer, with Wang Wen taking over from Zheng Chuanxian due to work adjustments [1] - Wang Wen has been a certified public accountant since 2011 and has been providing audit services to the company since 2025 [1] - The change in the quality reviewer will not affect the normal conduct of the company's 2025 financial statement and internal control audit [1]

证券代码：603301 证券简称：振德医疗 公告编号：2026-010 天健作为公司 2025 年度财务审计及内部控制审计机构，原委派 郑传贤先生作为项目质量复核人为公司提供审计服务。现因郑传贤先 生工作调整，天健委派王文先生接任郑传贤先生为项目质量复核人继 续为公司提供 2025 年度审计工作。 二、变更后项目复核人情况 1、基本信息 王文先生，2011 年起成为中国注册会计师，2011 年开始从事上 市公司审计，2011 年开始在天健执业，2025 年起为本公司提供审计 服务；近三年签署或复核楚环科技、泰福泵业、若羽臣等上市公司审 计报告。 2、独立性和诚信记录 振德医疗用品股份有限公司 关于变更项目质量复核人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 振德医疗用品股份有限公司（以下简称"公司"）于 2025 年 4 月 24 日和 2025 年 5 月 19 日分别召开了第三届董事会第二十次会议 和 2024 年年度股东大会，审议通过了《关于续聘会计师事务所的议 案》，同意聘任天健会计师事务所（特殊普通合伙） ...

Core Viewpoint - Zhendemedical experienced a decline of 2.37% on February 2, with a trading volume of 87.14 million yuan, indicating a potential market reaction to recent financial performance and trading activity [1]. Financing Summary - On February 2, Zhendemedical had a financing buy-in amount of 14.04 million yuan, with a net financing buy of 7.70 million yuan, reflecting strong investor interest despite the stock price drop [1]. - The total financing and securities balance reached 1.41 billion yuan, accounting for 7.89% of the circulating market value, which is above the 90th percentile of the past year, indicating a high level of leverage [1]. - The company had no shares repaid in the securities lending market on February 2, with 100 shares sold, resulting in a selling amount of 6,714 yuan, and a securities lending balance of 1.03 million yuan, also above the 80th percentile of the past year [1]. Financial Performance - For the period from January to September 2025, Zhendemedical reported a revenue of 3.18 billion yuan, representing a year-on-year growth of 1.88%, while the net profit attributable to shareholders decreased by 33.91% to 203 million yuan [2]. - The company has distributed a total of 1.46 billion yuan in dividends since its A-share listing, with 706 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, Zhendemedical had 23,600 shareholders, an increase of 4.06% from the previous period, with an average of 11,308 circulating shares per shareholder, a decrease of 3.90% [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited ranked fourth with an increase of 190,000 shares, while the fund "Zhaoshang Core Competitiveness Mixed A" exited the top ten list [3].

截至2026年1月30日收盘，振德医疗(603301)报收于68.77元，上涨2.87%，换手率0.77%，成交量2.04万 手，成交额1.39亿元。 当日关注点 交易信息汇总 资金流向 1月30日主力资金净流入832.09万元，占总成交额5.99%；游资资金净流出991.53万元，占总成交额 7.13%；散户资金净流入159.43万元，占总成交额1.15%。 公司公告汇总 振德医疗2026年第二次临时股东会会议材料 振德医疗拟对第二期员工持股计划（草案）及其管理办法进行修订，明确未解锁股份由公司回购注销， 并修订持有人权益处置方式。同时，公司拟回购第二期员工持股计划未解锁的1,829,868股股份，回购价 格为22.17元/股。此外，拟将已回购但未使用的129,442股及上述拟回购股份合计1,959,310股用途变更为 注销，公司总股本将由265,835,535股减少至263,876,225股，并相应修改公司章程，办理工商变更登记。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 来自交易信息汇总：1月30日主力资金净流入832. ...

Core Viewpoint - Zhendemedical (603301) has experienced a decline in stock price, closing at 68.77 yuan, down 3.06% from the previous week, with a current market capitalization of 18.282 billion yuan [1] Group 1: Stock Performance - As of January 30, 2026, Zhendemedical's stock closed at 68.77 yuan, down from 70.94 yuan the previous week, marking a decrease of 3.06% [1] - The stock reached a weekly high of 72.5 yuan on January 26 and a low of 66.17 yuan on January 30 [1] - The company's current total market capitalization is 18.282 billion yuan, ranking 13th out of 127 in the medical device sector and 1167th out of 5184 in the A-share market [1] Group 2: Company Announcements - Zhendemedical plans to revise its second employee stock ownership plan (draft) and management measures, specifying that unvested shares will be repurchased and canceled [2] - The company intends to repurchase 1,829,868 shares from the second employee stock ownership plan at a price of 22.17 yuan per share [2][3] - The total number of shares will decrease from 265,835,535 to 263,876,225 shares, with the corresponding amendments to the company's articles of association and registration changes [2][3]

Group 1 - The core concept of surgical infection control (SIC) involves a systematic infection prevention and control system throughout the surgical process, including preoperative assessment, sterile procedures during surgery, and postoperative wound care [1][8] - The SIC industry value chain consists of upstream components like disinfection materials and medical supplies, midstream focusing on product manufacturing and service integration, and downstream connecting to various healthcare institutions [1][10] - The demand for SIC is expected to rise due to the increasing number of surgeries in China, projected at approximately 96.39 million surgeries in 2023 [11] Group 2 - The global SIC market surpassed 20 billion yuan in 2019 and is projected to reach 27.06 billion yuan by 2026, growing at an annual rate of 4-5% [2][14] - China's SIC export market has grown significantly, reaching 740 million USD in 2023, with expectations to reach 1.078 billion USD by 2026 [2][17] - Major companies in the SIC industry include Aomei Medical, Zhend Medical, Jianerkang, and Aisheren Medical, with a predominant focus on overseas sales [2][20] Group 3 - The research team from Huajing Industry Research Institute employs various analytical models to assess the SIC industry's market capacity, competitive landscape, and future trends [3][27] - The report titled "2026-2032 China Surgical Infection Control Industry Market Research and Investment Opportunity Assessment" provides insights for enterprises and investment institutions [3][27] - The SIC industry is characterized by a combination of OEM and ODM business models, with some companies transitioning to self-branded sales [2][20]

《振德医疗2026年第二次临时股东会会议材料》 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 近日，振德医疗披露《2026年第二次临时股东会会议材料》，拟对第二期员工持股计划（草案）及其管 理办法进行修订，明确未解锁股份由公司回购注销，并修订持有人权益处置方式。同时，公司拟回购第 二期员工持股计划未解锁的1,829,868股股份，回购价格为22.17元/股。此外，拟将已回购但未使用的 129,442股及上述拟回购股份合计1,959,310股用途变更为注销，公司总股本将由265,835,535股减少至 263,876,225股，并相应修改公司章程，办理工商变更登记。 最新公告列表 截至2026年1月30日收盘，振德医疗（603301）报收于68.77元，较前一交易日上涨2.87%，最新总市值 为182.82亿元。该股当日开盘66.85元，最高68.84元，最低66.17元，成交额达1.39亿元，换手率为 0.77%。 ...